Norman Coleman, Gay Crawford to receive NCCS Stovall Award for advancing patient-centered care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Norman Coleman, associate director of NCI’s Radiation Research Program and Gay Crawford, founding director of Cancer CAREpoint, were named recipients of the National Coalition for Cancer Survivorship’s Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care.

Named for longtime CEO of NCCS and three-time cancer survivor Ellen Stovall, who died in 2016, the award aims to honor her memory and advocacy by annually recognizing individuals, organizations, or other entities that are innovators in improving cancer care.

Coleman has been affiliated with NCCS since working with Stovall on the NCAB/Senate Subcommittee to Evaluate the National Cancer Program in 1993. He helped form the New England Coalition for Cancer Survivorship while at Harvard. He is senior scientific advisor to the International Cancer Expert Corps, a non-government organization focusing on global disparities in cancer care.

Crawford has counseled thousands of patients and families over the past 44 years. Some of the programs she helped found include: Hospice of the Valley, the second non-profit hospice in California; Courageous Kids, an American Cancer Society program for children with cancer; the California Cancer Registry; the Colon Cancer Free Zone, advocating for colon cancer screening; and was successful in lobbying the insurance industry to pay for breast reconstructions for patients.

In 2011, she was invited to serve as the first chair of Stanford’s new South Bay Cancer Center Patient and Family Advisory Council, helping to develop the program and keep the focus on patient-focused care. In 2013, Crawford founded Cancer CAREpoint, a Silicon Valley based nonprofit organization.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login